What is Lactococcus lactis cremoris AM1 used for?

Lactococcus lactis cremoris AM1 is primarily studied in dairy microbiology for its cell-envelope proteinase (PrtP) activity, which breaks down milk caseins during cheese and fermented milk production. It is not currently marketed as a probiotic supplement with documented human health applications, and no clinical studies support its use for any therapeutic purpose.

Does Lactococcus lactis cremoris AM1 have any probiotic benefits?

As of available published research, no human clinical trials have established probiotic benefits for Lactococcus lactis cremoris AM1 specifically. While some L. lactis strains have been investigated for immune modulation and gut barrier support in other research contexts, these findings cannot be extrapolated to AM1 without strain-specific evidence. Its characterization remains confined to genetic diversity studies and fermentation microbiology.

How does Lactococcus lactis cremoris AM1 differ from other Lactococcus strains?

Lactococcus lactis cremoris AM1 has been genetically characterized within population diversity studies of L. lactis subsp. cremoris isolates, showing distinct proteinase gene variants and metabolic profiles compared to type strains like MG1363 or SK11. Its specific PrtP proteinase variant influences the spectrum of casein-derived peptides it generates during milk fermentation. However, these microbiological distinctions have not been linked to differential health outcomes in humans.

Is Lactococcus lactis cremoris AM1 safe to consume?

Lactococcus lactis subsp. cremoris as a subspecies holds GRAS (Generally Recognized As Safe) status from the FDA and Qualified Presumption of Safety (QPS) status from EFSA based on widespread, centuries-long use in dairy fermentation. AM1 itself has not been the subject of dedicated toxicology or safety studies, but exposure through fermented dairy products is considered low-risk for healthy adults. Immunocompromised individuals should consult a healthcare provider before consuming concentrated live bacterial preparations.

What enzymes does Lactococcus lactis cremoris AM1 produce?

Lactococcus lactis cremoris AM1 is characterized by its expression of a cell-envelope serine proteinase (PrtP), a subtilase-family enzyme anchored to the bacterial cell wall that initiates casein hydrolysis extracellularly. Intracellular peptidases including aminopeptidase N (PepN), proline iminopeptidase (PepI), and X-prolyl dipeptidyl aminopeptidase (PepX) further process the resulting oligopeptides. These enzymes collectively define the strain's proteolytic phenotype relevant to dairy fermentation technology.

What foods naturally contain Lactococcus lactis cremoris AM1?

Lactococcus lactis cremoris AM1 is primarily found in fermented dairy products, particularly certain cheeses and cultured milk beverages where it is used as a starter culture during fermentation. This strain is commonly employed in commercial dairy production for flavor development and texture, making cheese and buttermilk potential dietary sources. However, the presence and viability of this specific strain in finished products depends on fermentation conditions and post-processing handling.

Is there clinical research evidence supporting health claims for Lactococcus lactis cremoris AM1?

Currently, there is no published clinical research demonstrating health benefits in humans for Lactococcus lactis cremoris AM1. Existing research is limited to laboratory and microbiology studies examining its protein-fermenting properties and genetic characteristics in dairy applications. Any health claims about this strain remain unsupported by human clinical trials or outcome data.

Who should consider avoiding Lactococcus lactis cremoris AM1 supplements?

Individuals with severe dairy allergies or lactose intolerance may want to exercise caution, as this strain is derived from dairy fermentation processes and may retain trace allergens. People with compromised immune systems should consult a healthcare provider before using any probiotic supplement. Those with milk protein sensitivities should note that this strain's proteinase activity breaks down milk proteins, though the clinical relevance to individual tolerance is unknown.

Lactococcus lactis cremoris AM1

Lactococcus lactis subsp. cremoris AM1 is a dairy-associated lactic acid bacterium characterized by its cell-envelope proteinase (CEP) activity, which hydrolyzes casein proteins into bioactive peptides. Research on this specific strain is confined largely to microbiology and fermentation science, with no published human clinical trials establishing health benefits.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Emerging

Lactococcus lactis cremoris AM1 — Hermetica Encyclopedia

Origin & History

Lactococcus lactis subsp. cremoris AM1 is a lactic acid bacterium originally isolated from dairy environments, particularly from milk and cheese production facilities. This strain has been studied primarily for its role in dairy fermentation processes, where it produces proteinases that break down milk proteins.

Historical & Cultural Context

No traditional or historical medicinal use documented in the research. The strain's history is limited to its role in dairy fermentation and industrial cheese production.

Health Benefits

• No clinical health benefits documented - available research focuses only on microbiology and dairy fermentation properties
• Laboratory studies show proteinase activity on milk proteins, but no human health outcomes measured
• Genetic diversity studies exist, but without clinical relevance established
• Temperature-sensitive growth patterns documented in lab settings only
• No evidence quality available as no human trials have been conducted

How It Works

Lactococcus lactis cremoris AM1 expresses a cell-envelope-associated serine proteinase (PrtP) that cleaves bovine caseins—primarily αs1- and β-casein—into oligopeptide fragments via an extracellular subtilase-family catalytic mechanism. These peptide fragments are further transported intracellularly through oligopeptide permease (Opp) systems and degraded by cytoplasmic peptidases including PepN, PepC, and PepX to supply essential amino acids for bacterial growth. Whether this proteolytic cascade generates bioactive peptides with physiological relevance in humans has not been experimentally demonstrated for this specific strain.

Scientific Research

No clinical trials or meta-analyses were found in the research dossier. The available studies focus exclusively on laboratory characterization of plasmid replication, proteinase specificity, and cell wall properties without any human health endpoints or clinical outcomes measured.

Clinical Summary

No human clinical trials have been published specifically investigating Lactococcus lactis cremoris AM1. Available peer-reviewed literature is restricted to in vitro microbiological characterization and genetic diversity analyses of strain collections derived from dairy environments. No randomized controlled trials, observational cohort studies, or even pilot human studies have quantified outcomes such as gut colonization, immune modulation, or metabolic effects for this strain. The overall evidence base is preclinical and dairy-technological in nature, making any health claim unsupported by current data.

Nutritional Profile

Lactococcus lactis cremoris AM1 is a bacterial strain consumed in negligible biomass quantities; its direct macronutrient contribution is essentially zero in typical probiotic or fermented dairy applications. The strain produces lactic acid as its primary metabolic output during fermentation, contributing to acidification of dairy matrices. Documented bioactive outputs include exopolysaccharides (EPS) produced during fermentation, which remain in the food matrix and contribute trace structural polysaccharides. Its characterized AM1 proteinase system cleaves caseins (particularly β-casein and αs1-casein) into peptide fragments — some of which in related L. lactis cremoris strains have been associated with bioactive peptide generation (e.g., ACE-inhibitory peptides like IPP and VPP), though specific quantification for the AM1 strain in human-consumed matrices is not established in clinical literature. The strain produces B-vitamins (riboflavin, folate) as metabolic byproducts consistent with L. lactis species generally, though AM1-specific yields are unquantified. No direct fiber, fat, or significant mineral contribution is attributed to the organism itself.

Preparation & Dosage

No clinically studied dosage ranges are available for L. lactis cremoris AM1 as it has not been evaluated in human trials. No safety data, bioavailability studies, or recommended forms of administration have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactococcus lactis cremoris AM1 pairs mechanistically with Lactobacillus helveticus, as the latter's prolyl endopeptidases work downstream of AM1's casein-cleaving proteinase system to further hydrolyze casein-derived peptides into smaller ACE-inhibitory tripeptides (IPP, VPP), creating a sequential proteolytic cascade that neither organism achieves alone at the same efficiency. Pairing with prebiotic inulin or fructooligosaccharides (FOS at 3–5g doses) supports AM1's persistence in fermented matrices by providing fermentable substrate that selectively favors lactic acid bacteria survival and EPS production. Addition of Streptococcus thermophilus creates a well-documented proto-cooperation where S. thermophilus supplies formate and CO2 that stimulate AM1's growth kinetics, while AM1's proteinase activity releases amino acids (particularly glutamate and valine) that overcome S. thermophilus's amino acid auxotrophies, making this pairing standard in optimized dairy fermentation starters.

Safety & Interactions

Lactococcus lactis subspecies are generally regarded as safe (GRAS status in the United States and QPS status in the EU) based on their long history of use in food fermentation, but AM1 specifically has not undergone dedicated safety pharmacology studies. No documented drug interactions, adverse event profiles, or contraindications exist in the published literature for this strain. Immunocompromised individuals should exercise caution with any live bacterial preparation, as rare cases of bacteremia have been associated with lactic acid bacteria broadly. Pregnancy and lactation safety for AM1 specifically has not been evaluated; dietary exposure through fermented dairy is generally considered low-risk.